Related Experiment Video
Updated: Oct 14, 2025
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Engineered T-cell Receptor T Cells for Cancer Immunotherapy
Uri Greenbaum1, Ecaterina I Dumbrava2, Amadeo B Biter2
1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Engineering immune cells to target cancer is a rapidly advancing technology. The first commercial products, chimeric-antigen receptor (CAR) T cells, are now approved for hematologic malignancies. However, solid tumors pose a greater challenge for cellular therapy, in part because suitable cancer-specific antigens are more difficult to identify and surrounding healthy tissues are harder to avoid. In addition, impaired trafficking of immune cells to solid tumors, the harsh immune-inhibitory microenvironment, and variable antigen density and presentation help tumors evade immune cells targeting cancer-specific antigens. To overcome these obstacles, T cells are being engineered to express defined T-cell receptors (TCR). Given that TCRs target intracellular peptides expressed on tumor MHC molecules, this provides an expanded pool of potential targetable tumor-specific antigens relative to the cell-surface antigens that are targeted by CAR T cells. The affinity of TCR T cells can be tuned to allow for better tumor recognition, even with varying levels of antigen presentation on the tumor and surrounding healthy tissue. Further enhancements to TCR T cells include improved platforms that enable more robust cell expansion and persistence; coadministration of small molecules that enhance tumor recognition and immune activation; and coexpression of cytokine-producing moieties, activating coreceptors, or mediators that relieve checkpoint blockade. Early-phase clinical trials pose logistical challenges involving production, large-scale manufacturing, and more. The challenges and obstacles to successful TCR T-cell therapy, and ways to overcome these and improve anticancer activity and efficacy, are discussed herein.
Insights
Engineered T-cell receptor (TCR) T cells offer a promising approach to target solid tumors, overcoming limitations of CAR T cells by targeting intracellular antigens. Enhancements aim to improve efficacy and overcome challenges in TCR T-cell therapy for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
- Cellular Therapy
Background:
- Chimeric-antigen receptor (CAR) T-cell therapy is approved for hematologic cancers but faces challenges in solid tumors.
- Solid tumors present difficulties including antigen identification, immune evasion, and a hostile microenvironment, hindering CAR T-cell efficacy.
- T-cell receptor (TCR) engineered T cells offer an alternative by targeting intracellular antigens, expanding the scope of cellular therapy.
Purpose of the Study:
- To discuss the challenges and potential solutions for T-cell receptor (TCR) T-cell therapy in treating solid tumors.
- To highlight the advantages of TCR T cells over CAR T cells for solid tumor targeting.
- To explore strategies for enhancing the efficacy and overcoming obstacles in TCR T-cell therapy.
Main Methods:
- Engineering T cells to express T-cell receptors (TCRs) targeting intracellular tumor antigens presented on MHC molecules.
- Tuning TCR affinity for improved tumor recognition and differentiation from healthy tissues.
- Implementing enhancement strategies such as improved cell expansion platforms, co-administered small molecules, and co-expression of immune-modulating moieties.
Main Results:
- TCR T cells target a broader range of tumor-specific antigens compared to CAR T cells.
- Adjustable TCR affinity allows for better recognition of tumors with variable antigen presentation.
- Enhancement strategies show potential for improved T-cell persistence, tumor infiltration, and anti-cancer activity.
Conclusions:
- TCR T-cell therapy presents a significant advancement for solid tumor treatment, addressing limitations of current cellular therapies.
- Overcoming challenges related to manufacturing, clinical trial logistics, and optimizing therapeutic enhancements is crucial for clinical success.
- Further research and development in TCR T-cell engineering hold promise for improving cancer treatment efficacy.
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...